SIRPA and head and neck cancer: Selective SIRPα combination therapy with CPIs (ezabenlimab, pembrolizumab) yielded study-level ORR of 18.8% to 20.0% in patients with recurrent colorectal, endometrial, and head and neck cancers (Table 3) (30, 33, 34).